What Dewei Treats: Main Uses and Benefits

The therapeutic use of Dewei (Felodipine) is defined by its role in the long-term management of cardiovascular conditions, offering sustained control over two primary clinical domains. The medication is used for lowering blood pressure, which is generally considered relevant for reducing cardiovascular risk.

Dewei is commonly used for the sustained management of elevated systemic blood pressure (essential hypertension) and for the prophylaxis of symptoms associated with chronic stable angina pectoris. Controlling this pressure may contribute to reducing overall cardiovascular risk factors, and supports the long-term management of vascular strain. The treatment is relevant for episodes where chest discomfort or pain arises from symptoms linked to organ-specific functional stress, typically during exertion. This supportive action may assist with managing symptoms that create noticeable physiological strain and helps maintain a sense of stability when symptoms are more noticeable.

“This medication is applied in clinical settings that involve chronic or sustained symptom patterns related to systemic circulatory imbalance.”

This supportive action contributes to improved comfort during periods of heightened symptoms, assists with maintaining functional stability during symptomatic periods, and offers symptomatic relief that helps patients cope more steadily.

---

Quick Fact: Management of Systemic Imbalance Dewei is commonly used to help with symptoms related to heightened physiological activity and to manage conditions presenting with systemic discomfort, assisting with maintaining functional stability.

Eligibility Map: Who Can and Cannot Use Dewei (Felodipine) — Official Regulatory Information

Dewei (Felodipine) is officially approved for use only in the adult population (18 years and older). Eligibility is strictly governed by medical condition and physiological status, as defined in government regulatory labeling.

---

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults with essential hypertension or for the prophylaxis of chronic stable angina pectoris.
Populations for whom use is not recommended	Women who are breastfeeding; patients with severe hepatic impairment.
Populations for whom use is contraindicated	Patients with known hypersensitivity to felodipine; Pregnancy; patients with unstable angina pectoris, acute myocardial infarction, or decompensated heart failure.
Age-related eligibility rules	Paediatric population (under 18 years): Safety and efficacy have not been established.
Condition-specific eligibility rules	Use in renal impairment is generally permitted; severe hepatic impairment restricts use.

---

Eligibility classifications (high-level)

Classification	Status as Defined in Official Documents
Contraindicated	Pregnancy, Hypersensitivity, Acute Cardiac Events.
Not Established	Paediatric Population.

Connection to the overall eligibility profile Official regulatory documents establish strict boundaries for Dewei use by contraindicating the medicine in patients with specific cardiac instabilities and hypersensitivity. Use is further excluded for the paediatric population where data is insufficient, and for states like pregnancy and severe hepatic impairment, thereby limiting standard eligibility to the approved adult demographic.

️ Interactions with other medicines and products

The official interaction profile for Dewei (Felodipine) is defined by its metabolism and the documented resulting effect on drug exposure.

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Strong/Potent CYP3A4 Inhibitors (e.g., certain azole antifungals, macrolide antibiotics); CYP3A4 Inducers (e.g., certain anticonvulsants); Other Antihypertensive Agents (e.g., Beta-Blockers).
Specific interacting medicines (if explicitly listed)	Itraconazole, Erythromycin, Cimetidine, Phenytoin, Carbamazepine, Rifampin, Metoprolol.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction (CYP3A4 Metabolism): Felodipine is a sensitive substrate of the CYP3A4 enzyme, leading to significant changes in plasma concentrations (AUC and Cmax) upon co-administration.
Population-specific interaction notes (if applicable)	Plasma concentrations are significantly elevated in patients with hepatic impairment, which may exacerbate the effects of interactions that lead to increased exposure.
Interaction-related restrictions	Grapefruit Juice consumption must be avoided or severely limited as it causes more than a two-fold increase in plasma concentrations.

Interaction Classifications (High-Level)

Classification Property	Regulatory Statement
Interaction severity classification	The combination with Itraconazole is formally classified as Contraindicated.
Interaction-context constraints	The product is subject to additive hypotensive effects when co-administered with other blood pressure-lowering agents, including the substance Alcohol.

Resulting Interaction Structure

Official interaction statements confirm that co-administration with strong CYP3A4 inhibitors like Itraconazole is prohibited due to the several-fold increase in exposure that cannot be feasibly managed. Conversely, use with CYP3A4 inducers, such as Rifampin, significantly reduces plasma levels, potentially diminishing the documented effects of the medicine. The official profile is therefore structured around mandatory restrictions based on the potential for dramatic, enzyme-mediated alteration of drug concentrations.

How Dewei Works

---

Modulating Vascular Calcium Channel Activity

Dewei's active ingredient, Felodipine, operates by selectively acting as an antagonist of the L-type Voltage-Gated Calcium Channels (L-VGCCs). These channels are primarily located in the smooth muscle cells lining the small resistance arteries (arterioles). This highly specific molecular interaction directly prevents the influx of extracellular calcium ( Ca^2+) ions, which are the fundamental biochemical trigger required for muscle contraction.

---

Reducing Peripheral Vascular Resistance

The blockade of calcium entry interrupts the Excitation-Contraction Coupling pathway within the arteriolar smooth muscle fibers, causing them to relax and widen—a process known as vasodilation. This cascade leads to a profound reduction in Peripheral Vascular Resistance (PVR). By lowering the systemic resistance, the mechanism directly reduces the mechanical force opposing ventricular ejection (afterload).

---

Limitations in Venous and Cardiac Selectivity

The mechanism exhibits high selectivity for arterial resistance vessels and has minimal functional effect on venous smooth muscle. Furthermore, Felodipine demonstrates inherently lower affinity for L-type channels in the myocardium, directing the bulk of its physiological action toward the peripheral circulation rather than directly modifying cardiac contractility.

How to Use Dewei

Dewei is administered orally as an extended-release tablet and is utilized as part of a long-term strategy for managing systemic blood pressure and stable angina pectoris. The medication's design as an extended-release formulation dictates a simplified dosing schedule and specific administration requirements necessary to maintain its controlled 24-hour drug delivery.

---

Official Dosing and Administration Protocol

The standard approach involves taking the tablet once daily in the morning, which is consistent with its extended-release properties. The tablets must be swallowed whole and must not be crushed, cut, or chewed, as this action compromises the controlled-release mechanism and may alter absorption.

Usage Parameter	Official Instruction
Standard Adult Dose	Starting dose is typically 5 mg once daily for hypertension and angina.
Maintenance Range	Doses range from 2.5 mg to 10 mg once daily.
Dose Adjustment	Titration should occur gradually, generally at intervals of at least two weeks.
Food Relationship	May be taken without food or with a light, non-fatty meal.
Fluid Restriction	Concomitant administration with grapefruit juice must be avoided due to its effect on bioavailability.

---

Population-Specific Use

Specific dosage considerations are mandated for certain patient groups. A reduced initial dose of 2.5 mg once daily is specified for both older adults and patients with diagnosed hepatic impairment. Conversely, no specific initial dosage adjustment is typically required for patients with renal impairment.

Research evidence / Overview of studies for Dewei (Felodipine)

---

Evidence for use in Elevated Systemic Blood Pressure

Research for Dewei (Felodipine) has involved high-quality research designs, including Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Researchers used these study designs to examine the effects of Felodipine across diverse groups of adults, including older individuals and patients with other underlying cardiovascular risk factors. Studies monitored several key outcomes, including direct measurement of changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Furthermore, large-scale, long-term trials were applied in research examining how the incidence of major events evolved in the observed populations, such as a stroke or a myocardial infarction. While the evidence base is substantial, long-term studies reporting cardiovascular outcomes are often derived from trials primarily designed to compare Felodipine against other types of blood pressure medications in defined populations.

---

Evidence for use in Chronic Stable Angina Pectoris

Dewei was also evaluated in research exploring how symptoms change over time in conditions characterized by stable angina pectoris. This research primarily consists of short-term Randomized Controlled Trials and crossover studies. Studies were conducted in adult patients with documented chest discomfort that typically occurs during physical exertion. Researchers monitored the frequency of anginal attacks over a week and tracked changes in the patient's need for other relief medications. Research also examined outcomes reflecting daily functioning, including measurement of total exercise duration and the time to reach a specific marker of ischemia during controlled exercise testing. The research for stable angina includes studies that monitored responses over relatively defined and short time intervals (e.g., 4 to 8 weeks). Comparative evidence for long-term event reduction specifically for angina is still limited.

---

Research in Special Populations

Research studies for Dewei have included a variety of patient groups. Older adults with hypertension were included in key clinical studies, and the data show patterns related to outcomes in this group. However, data for certain groups remain insufficient. For instance, evidence describing long-term outcomes for very specific, small subgroups—or for populations not typically included in adult cardiovascular trials—is more limited.

Key Studies & References

1. Felodipine Extended-Release Tablets: Package Insert / Prescribing Info (Regulatory Document)
2. Felodipine Event Reduction Study (FEVER) - ClinicalTrials.gov
3. Calcium channel blockers and cardiovascular outcomes: a systematic review and meta-analysis of randomised trials

Common questions about Dewei (FAQ)

Q: What is Dewei and what is it used for?

A: Dewei is a prescription medication used to manage certain types of chronic pain. It belongs to a class of drugs known as selective gamma-aminobutyric acid modulators. It works by affecting specific neurotransmitters in the brain and nervous system, which helps to decrease the feeling of pain.

---

Q: How should I take Dewei?

A: You should take Dewei exactly as your doctor prescribes. The dose and schedule will depend on your specific medical condition and how you respond to the treatment.

• Swallow the tablets whole with a glass of water.
• You can take Dewei with or without food.
• Do not stop taking Dewei suddenly without talking to your doctor, as this can cause withdrawal symptoms.

---

Q: What should I do if I miss a dose?

A: If you miss a dose of Dewei:

• Take the missed dose as soon as you remember.
• If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule.
• Do not take two doses at the same time to make up for a missed dose.
• Contact your healthcare provider if you are unsure what to do.

---

Q: What are the common side effects of Dewei?

A: Common side effects of Dewei often include:

• Dizziness or lightheadedness
• Drowsiness or fatigue
• Headache
• Dry mouth
• Nausea

These side effects are usually mild and may lessen as your body adjusts to the medication. If any side effect becomes severe or bothersome, speak with your doctor.

---

Q: Can Dewei cause drug dependence or withdrawal?

A: Yes, Dewei can cause physical dependence with long-term use. Suddenly stopping the medication or rapidly reducing the dose can lead to withdrawal symptoms such as anxiety, sweating, tremors, and difficulty sleeping.

Always follow your doctor's instructions for tapering the dose when discontinuing treatment to minimize withdrawal effects.

---

Q: Is it safe to drive or operate machinery while taking Dewei?

A: Dewei can cause dizziness and drowsiness. Due to these possible effects, you should not drive, operate heavy machinery, or participate in other activities that require mental alertness until you know how the medication affects you. Alcohol and other sedating medications can increase these effects, so they should be used with caution.

Storage and Handling Requirements

Official regulatory labeling dictates that Dewei (Felodipine Extended-Release Tablets) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and excess moisture. To maintain its stability, the medication must be kept in its original, tightly closed, light-resistant container. The extended-release tablets must not be crushed, chewed, or divided. For safety, the medicine must be stored out of the sight and reach of children at all times.

Disposal Instructions

Disposal of unused or expired tablets should be managed through a formal drug take-back program. If this option is unavailable, the medicine, which is not on the FDA's flush list, should be mixed with an undesirable substance (e.g., dirt) in a sealed bag and placed in the household trash, in accordance with local environmental regulations.